CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $9.91M, lower than 95% of all stocks globally
- PositionGross margin is 11.8%, lower than 95% of its Biotechnology peers (median 67.1%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
66.88MCNY9.91M · vs all stocks (USD)
Revenue (TTM)
618.17MCNY91.59M · vs all stocks (USD)
Profit Margin
-20.89%vs Biotechnology peers
Beta
0.0670xvs all stocks
52-Week Change
-97.18%vs all stocks
Market Capitalization
66.88MCNY9.91M · vs all stocks (USD)
Enterprise Value
163.33MCNY24.20M · vs all stocks (USD)
Price to Sales (TTM)
0.1082xvs Biotechnology peers
Price to Book (MRQ)
0.1800xvs Biotechnology peers
Enterprise to Revenue
0.2640xvs Biotechnology peers
Enterprise to EBITDA
18.44xvs Biotechnology peers
Gross Margin
11.76%vs Biotechnology peers
Profit Margin
-20.89%vs Biotechnology peers
Operating Margin
-1.23%vs Biotechnology peers
Return on Assets (TTM)
-3.41%vs Biotechnology peers
Return on Equity (TTM)
-29.06%vs Biotechnology peers
Revenue (TTM)
618.17MCNY91.59M · vs all stocks (USD)
Revenue per Share (TTM)
3.51CNYUpdated Jul 15, 2026Quarterly Revenue Growth
183.80%vs Biotechnology peers
Gross Profit (TTM)
48.23MCNY7.15M · vs all stocks (USD)
EBITDA (TTM)
35.25MCNY5.22M · vs all stocks (USD)
Net Income (TTM)
-129.12MCNY-19.13M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
242.45%vs Biotechnology peers
Operating Cash Flow (TTM)
15.89MCNY2.35M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
88.28MCNY13.08M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
4.01MCNYFY2025 · Dec 31, 2025Revenue
518.76MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
445.22MCNYFY2025 · Dec 31, 2025Gross Profit
73.55MCNYFY2025 · Dec 31, 2025Operating Income
-20.51MCNY-3.04M · vs all stocks (USD)
Pre-tax Income
-114.93MCNYFY2025 · Dec 31, 2025Income Tax Expense
6.93MCNYFY2025 · Dec 31, 2025Net Income
-121.86MCNYFY2025 · Dec 31, 2025EBIT
-107.73MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
35.25MCNYFY2025 · Dec 31, 2025Research & Development
16.18MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
33.04MCNYFY2025 · Dec 31, 2025Other Operating Expenses
5.92MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.06MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
7.20MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.6885CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.6885CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
175.99MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
175.99MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-121.86MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
686.53KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-183.87MCNYFY2025 · Dec 31, 2025Free Cash Flow
-205.50MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
58.89MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-121.86MCNYFY2025 · Dec 31, 2025Other Non-cash Items
8.00MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-75.84MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
5.83MCNYFY2025 · Dec 31, 2025Capital Expenditures
-21.63MCNYFY2025 · Dec 31, 2025Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025Purchase of Investments
-5.00MCNYFY2025 · Dec 31, 2025Sale of Investments
5.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-21.63MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
164.90MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-134.73MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-6.30MCNYFY2025 · Dec 31, 2025Other Financing Charges
-10.38MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
13.49MCNYFY2025 · Dec 31, 2025Shares Outstanding
176.00MSharesUpdated Jul 15, 2026Float Shares
62.56MSharesUpdated Jul 15, 2026% Held by Insiders
69.17%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash (MRQ)
29.21MCNY4.33M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1660CNYUpdated Jul 15, 2026Total Debt (MRQ)
115.68MCNY17.14M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3061xvs Biotechnology peers
Current Ratio (MRQ)
0.8500xvs Biotechnology peers
Book Value per Share (MRQ)
2.11CNYUpdated Jul 15, 2026Total Assets
832.10MCNY123.28M · vs all stocks (USD)
Total Current Assets
344.70MCNYFY2025 · Dec 31, 2025Total Liabilities
447.95MCNYFY2025 · Dec 31, 2025Total Non-current Assets
487.40MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
37.58MCNYFY2025 · Dec 31, 2025Total Current Liabilities
410.37MCNYFY2025 · Dec 31, 2025Cash
60.90MCNYFY2025 · Dec 31, 2025Cash Equivalents
117.12KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
61.02MCNYFY2025 · Dec 31, 2025Accounts Receivable
93.73MCNYFY2025 · Dec 31, 2025Inventory
80.38MCNYFY2025 · Dec 31, 2025Accounts Payable
99.30MCNYFY2025 · Dec 31, 2025Short-term Debt
114.70MCNYFY2025 · Dec 31, 2025Other Current Liabilities
58.86MCNYFY2025 · Dec 31, 2025Long-term Debt
13.97MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
6.33MCNYFY2025 · Dec 31, 2025Common Stock (Book)
176.00MCNYFY2025 · Dec 31, 2025Retained Earnings
-104.43MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
384.15MCNY56.92M · vs all stocks (USD)
Treasury Stock
0.00CNYFY2025 · Dec 31, 202552-Week Low
0.3000CNYUpdated Jul 15, 202652-Week High
17.49CNYUpdated Jul 15, 202652-Week Change
-97.18%vs all stocks
Beta
0.0670xvs all stocks
50-Day MA
6.39CNYUpdated Jul 15, 2026200-Day MA
11.12CNYUpdated Jul 15, 2026Avg 10-Day Volume
25.42MSharesUpdated Jul 15, 2026Avg 30-Day Volume
10.51MSharesUpdated Jul 15, 2026Diluted EPS (TTM)
-0.7300CNYUpdated Jul 15, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Sharp Decline With Volume And Volatility Expansion
A steep fall on heavy volume, leaving the price far below its peak.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 11.8%, lower than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: 0.12Industry median: 0.67Industry P5: 0.14Peers compared: 261
Current ratio is 0.85×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.85Industry median: 5.64Industry P5: 1.06Peers compared: 261
Price-to-book is 0.18×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.18Industry median: 2.97Industry P5: 1.03Peers compared: 261
Financial Health
Altman Z-Score 0.01: distress zoneCritical
Altman Z-Score: 0.01
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $9.91M, lower than 95% of all stocks globallySignificant
Market cap (USD): 9,908,940.8Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Crism Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cizzle Biotechnology Holdings Plc
Tier 1ProductionApproval-Gated PipelineRule
Genflow Biosciences Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
BioLineRx Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Thalia Therapeutics Plc
Tier 1ProductionApproval-Gated PipelineRule
Sulzer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
XTL Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Purple Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
TheracryF PLC
Tier 1ProductionApproval-Gated PipelineRule
Nuformix Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Huatu Cendes Co., Ltd.
3 interpretationsIndustry-Benchmarked Return on Capital ElevatedUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedSharp Decline With Volume And Volatility Expansion
Wintao Communications Co.
3 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedSharp Decline With Volume And Volatility Expansion
Elitecon International Ltd.
3 interpretationsIndustry-Benchmarked Return on Capital ElevatedDecline With Range Expansion And DrawdownSharp Decline With Volume And Volatility Expansion